Personalized Pharmacotherapy for Type 2 Diabetes: Evidence-Based Drug Selection
Review explores evidence for personalized T2D pharmacotherapy including patient characteristics that predict optimal response to GLP-1 drugs versus other medication classes.
Quick Facts
What This Study Found
Review explores evidence for personalized T2D pharmacotherapy including patient characteristics that predict optimal response to GLP-1 drugs versus other medication classes.
Key Numbers
Systematic review examining dysregulated miRNA expression detected in various patient samples and their correlation with drug response.
How They Did This
In publication.
Why This Research Matters
Relevant to peptide therapeutics.
The Bigger Picture
Advances peptide therapeutic knowledge.
What This Study Doesn't Tell Us
In publication.
Questions This Raises
- ?Long-term implications?
- ?Comparison to evidence?
- ?Next research?
Trust & Context
- Key Stat:
- Key finding Review explores evidence for personalized T2D pharmacotherapy including patient characteristics that
- Evidence Grade:
- Based on study design.
- Study Age:
- Published in 2025.
- Original Title:
- Exploring the Evidence for Personalized Pharmacotherapy in Type 2 Diabetes-A Systematic Review.
- Published In:
- Journal of personalized medicine, 15(11) (2025)
- Authors:
- Altabas, Velimir, Marinković Radošević, Jelena
- Database ID:
- RPEP-09910
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What does this mean?
Review explores evidence for personalized T2D pharmacotherapy including patient characteristics that predict optimal response to GLP-1 drugs versus other medication classes.
How reliable?
Consult publication.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09910APA
Altabas, Velimir; Marinković Radošević, Jelena. (2025). Exploring the Evidence for Personalized Pharmacotherapy in Type 2 Diabetes-A Systematic Review.. Journal of personalized medicine, 15(11). https://doi.org/10.3390/jpm15110539
MLA
Altabas, Velimir, et al. "Exploring the Evidence for Personalized Pharmacotherapy in Type 2 Diabetes-A Systematic Review.." Journal of personalized medicine, 2025. https://doi.org/10.3390/jpm15110539
RethinkPeptides
RethinkPeptides Research Database. "Exploring the Evidence for Personalized Pharmacotherapy in T..." RPEP-09910. Retrieved from https://rethinkpeptides.com/research/altabas-2025-exploring-the-evidence-for
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.